#USA #Anixa Biosciences #San Jose #CAR-T therapy #Ovarian Cancer

Anixa Biosciences Advances Cancer Treatment

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biopharmaceutical company committed to innovating cancer therapies, has made headlines with the recent announcement regarding their ongoing Phase 1 clinical trial. This trial is examining a groundbreaking chimeric antigen receptor-T cell (CAR-T) therapy specifically targeting recurrent ovarian cancer.

Overview of the Clinical Trial

Conducted in collaboration with Moffitt Cancer Center, the clinical trial aims to assess the safety and efficacy of this novel CAR-T treatment. As of August 18, 2025, Anixa successfully treated the second patient in the fourth cohort of the trial, a notable milestone suggesting effective progression.

In this fourth cohort, participants are administered a dose of three million CAR-positive cells per kilogram of body weight, representing a substantial increase of 30-fold over earlier dosage levels. Impressively, no dose-limiting toxicities (DLTs) have been identified so far, which is a significant indicator of the therapy’s potential safety profile.

The Science Behind the Therapy

Anixa's CAR-T technology uniquely focuses on the follicle-stimulating hormone receptor (FSHR), which is predominantly expressed on ovarian cells and certain cancer cells but not on healthy tissues. This specificity is crucial as it could mean fewer side effects compared to traditional therapies, thereby enhancing treatment quality for patients battling recurrent ovarian cancer.

The ongoing Phase 1 trial, registered under NCT05316129, is not only targeting the safety of this new approach but is also designed to discover the maximum tolerated dose and to investigate any initial signs of clinical effectiveness.

Dr. Amit Kumar, the Chairman and CEO of Anixa Biosciences, commented on the therapy's progress, stating, "Our therapy continues to demonstrate a favorable safety profile, even at significantly higher cell doses. While this study is primarily designed to assess safety, we remain encouraged by early indications of potential efficacy as the trial progresses."

Collaborative Efforts and Technology Licensing

The technological foundation of Anixa’s CAR-T program was developed by Dr. Jose R. Conejo-Garcia, associated with Duke University School of Medicine. This collaboration exemplifies Anixa's commitment to partnering with prestigious research institutions to harness the latest advancements in immunotherapy.

The trial is led by Dr. Robert Wenham at Moffitt Cancer Center, a facility known for its pioneering work in next-generation cancer therapies, including CAR-T treatments and tumor-infiltrating lymphocytes (TILs). Anixa has acquired an exclusive worldwide license for the FSHR-targeting CAR-T technology, further solidifying its position in the competitive oncology landscape.

Expanding Cancer Therapeutics

Anixa's broader therapeutic portfolio includes a dedicated immunotherapy program for ovarian cancer and collaborations with Cleveland Clinic for developing vaccines against various cancers, including breast and ovarian cancer. Their innovative approach – the chimeric endocrine receptor-T cell (CER-T) technology – differentiates itself by utilizing the natural ligand of the FSHR receptor rather than traditional antibody fragments, potentially opening new avenues in cancer immunotherapy.

In conclusion, the recent advancements made by Anixa Biosciences showcase not only their dedication to combatting ovarian cancer but also highlight the continuous evolution of cancer treatment modalities. With their unique partnerships and innovative technologies, Anixa is poised to make significant contributions to the field of oncology, potentially changing the lives of patients affected by cancer. Visit Anixa's website for more information about their groundbreaking work.